NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/05/2024
Voltar para busca
Dado oficial do USPTO
YOCHANRA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
28/05/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
09/05/2022
Data de registro
28/05/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/05/2024
Última transação
28/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Código do desenho
4
Tipo de titular
03
Localização do titular
Nanjing, Jiangsu, CN
Examinador
MAYES, LAURIE ANN
Unidade examinadora
L10
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
TransThera Sciences (Nanjing), Inc.
Representantes
Michael T. Smith Birch Stewart Kolasch & Birch, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; drugs for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemico-pharmaceutical preparations for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biological preparations for medical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; bulk medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; biochemical medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; chemical preparations for pharmaceutical purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines in the nature of tablets for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders; medicines for human purposes for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders in the nature of capsule; injectable medicines for treatment of cancercardiovascular diseases and disordersmetabolic diseases and disordersanemia and associated anemia diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disordersnervous system diseases and disordersinfection and inflammationskeletal or chondrocyte disordersimmune and autoimmune diseaseshematological disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
28/05/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/02/2024
OTHE
CASE RETURNED TO EXAMINATION
08/02/2024
IUCN
NOTICE OF ALLOWANCE CANCELLED
08/02/2024
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
07/02/2024
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
07/02/2024
APET
ASSIGNED TO PETITION STAFF
06/02/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
20/01/2024
EX1G
SOU EXTENSION 1 GRANTED
18/01/2024
EXT1
SOU EXTENSION 1 FILED
18/01/2024
EEXT
SOU TEAS EXTENSION RECEIVED
18/01/2024
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
10/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/11/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/11/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/11/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/11/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/11/2023
WOAG
WITHDRAWAL OF ATTORNEY GRANTED
12/09/2023
WOAR
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
12/09/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
18/07/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/05/2023
PUBO
PUBLISHED FOR OPPOSITION
23/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/04/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/04/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/04/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/03/2023
GNRT
NON-FINAL ACTION E-MAILED
03/03/2023
CNRT
NON-FINAL ACTION WRITTEN
03/03/2023
DOCK
ASSIGNED TO EXAMINER
25/02/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/05/2022
NWAP
NEW APPLICATION ENTERED
12/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace YOCHANRA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.